依维莫司药物洗脱支架的发展进程
|
摘要
背景:药物洗脱支架将金属支架的机械支架性能与一种抗增殖药物的特异性结合起来,能够有效的减少支架对血管的损伤、支架内再狭窄和血栓的发生率,并降低晚期不良事件的风险。目的:探索依维莫司药物洗脱支架研究进展。方法:以"依维莫司;everolimus;stent;drug-eluting stents;everolimus drug-eluting stents"等为关键词,在中国知网数据库、PubMed、EMBAES数据库中进行检索,排除与文章不相关的、老旧的、重复的文献,对保留的61篇文献进行归纳、分析与总结。结果与结论:依维莫司药物洗脱支架目前临床上以钴铬依维莫司药物洗脱支架最为常见,可有效抑制内膜增生和炎症反应发生,减少支架内血栓的发生率。虽然新型依维莫司药物洗脱支架的出现解决了依维莫司药物洗脱支架的一些问题,如血小板黏附、平滑肌细胞增殖、血管舒缩及血管内皮细胞活性,但还有一些问题需要继续研究。
BACKGROUND: Drug-eluting stents, which combine the mechanical properties of metal stents with the specificity of an anti-proliferative drug, can effectively reduce the incidence of stent injury, restenosis and thrombosis, and reduce the risk of late adverse events. OBJECTIVE: To review the progress of everolimus-eluting stents. METHODS: The key words of "everolimus, stent, drug-eluting stents, everolimus drug-eluting stents" were used for literature retrieval in CNKI, PubMed and EMBASE databases. Unrelated, old and duplicated literatures were excluded, and 61 retained literatures were summarized, analyzed and summarized.RESULTS AND CONCLUSION: Cobalt chromium-everolimus eluting stent is the most common everolimus-eluting stent, which can effectively inhibit intimal hyperplasia and inflammation and reduce the incidence of stent thrombosis. Although the emergence of new everolimus-eluting stents has solved some problems of existing everolimus-eluting stents, such as platelet adhesion, smooth muscle cell proliferation, vasomotion and vascular endothelial cell viability, there are still some problems that need to be further studied.
BACKGROUND: Drug-eluting stents, which combine the mechanical properties of metal stents with the specificity of an anti-proliferative drug, can effectively reduce the incidence of stent injury, restenosis and thrombosis, and reduce the risk of late adverse events. OBJECTIVE: To review the progress of everolimus-eluting stents. METHODS: The key words of "everolimus, stent, drug-eluting stents, everolimus drug-eluting stents" were used for literature retrieval in CNKI, PubMed and EMBASE databases. Unrelated, old and duplicated literatures were excluded, and 61 retained literatures were summarized, analyzed and summarized.RESULTS AND CONCLUSION: Cobalt chromium-everolimus eluting stent is the most common everolimus-eluting stent, which can effectively inhibit intimal hyperplasia and inflammation and reduce the incidence of stent thrombosis. Although the emergence of new everolimus-eluting stents has solved some problems of existing everolimus-eluting stents, such as platelet adhesion, smooth muscle cell proliferation, vasomotion and vascular endothelial cell viability, there are still some problems that need to be further studied.
引文
[1]Lawton J,McGrath J,Jones JS,et al.Treatment of coronary artery disease in an anomalous coronary artery by placement of an intracoronary stent.Cathet Cardiovasc Diagn.1997;41(2):185-188.
[2]Yang JH,Choi SH,Song YB,et al.Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction.Am J Cardiol.2013;112(5):623-629.
[3]Kong KL,Fong AYY,Mejin M,et al.PM222 Early Clinical Outcomes In Patients Electively Implanted With Everolimus And Non-Everolimus Drug Eluting Stents:Impact Of Platelet Function Testing Following Pretreatment With Aspirin And Clopidogrel.Global Heart.2014;9(1,Supplement):e108.
[4]Hayashi T,Kotani J,Ishibashi-Ueda H,et al.Thrombus-related focal in-stent restenosis after everolimus-eluting stent implantation.Heart Vessels.2014;29(2):273-277.
[5]Stone GW,Midei M,Newman W,et al.Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease:a randomized trial.JAMA.2008;299(16):1903-1913.
[6]Palmerini T,Kirtane AJ,Serruys PW,et al.Stent thrombosis with everolimus-eluting stents:meta-analysis of comparative randomized controlled trials.Circ Cardiovasc Interv.2012;5(3):357-364.
[7]Hasskarl J.Everolimus.Recent Results Cancer Res.2014;201:373-392.
[8]Martinet W,Verheye S,De Meyer GR.Everolimus-induced mTORinhibition selectively depletes macrophages in atherosclerotic plaques by autophagy.Autophagy.2007;3(3):241-244.
[9]Lebwohl D,Anak O,Sahmoud T,et al.Development of everolimus,a novel oral mTOR inhibitor,across a spectrum of diseases.Ann N Y Acad Sci.2013;1291:14-32.
[10]von Birgelen C,van der Heijden LC,Basalus MW,et al.Five-Year Outcome After Implantation of Zotarolimus-and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients:A Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiol.2017;2(3):268-276.
[11]Sotomi Y,Suwannasom P,Tenekecioglu E,et al.Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold:from bench to clinical use.Expert Rev Cardiovasc Ther.2015;13(10):1127-1145.
[12]Gatto P,Dumonteil N,Boudou N,et al.Incomplete stent apposition and very late stent thrombosis after everolimus eluting stent implantation and dual antiplatelet therapy interruption.Acase of OCT guided therapy.Int J Cardiol.2015;180:52-54.
[13]Ahn JM,Park GM,Cho YR,et al.Comparison of Platinum Chromium Versus Cobalt Chromium Everolimus-eluting Stent in Real World Practice:Outcomes from the Multicenter Prospective IRIS-DES Registry.Am J Cardiol 2013;111(7,Supplement):2B.
[14]Barbash IM,Minha S,Torguson R,et al.Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.J Invasive Cardiol.2014;26(4):154-160.
[15]Morino Y,Terashita D,Otake H,et al.Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction:results from a multicenter prospective optical coherence tomography study(MECHANISM-AMI 2-week follow-up study).Cardiovasc Interv Ther.2018.doi:10.1007/s12928-017-0507-4.
[16]Buszman PP,Michalak MJ,Pruski M,et al.Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.Cardiol J.2016;23(6):657-666.
[17]Calfon Press MA,Mallas G,Rosenthal A,et al.Everolimus-eluting stents stabilize plaque inflammation in vivo:assessment by intravascular fluorescence molecular imaging.Eur Heart JCardiovasc Imaging.2017;18(5):510-518.
[18]Shibata Y,Yano H,Horinaka S,et al.Everolimus-eluting stent suppresses chronic inflammatory reaction compared with bare metal stent in off-label patients.Eur Heart J.2013;34(Suppl 1):4807-4817.
[19]Karakulak UN,Yorgun H,?ahiner L,et al.OP-008 Evaluation of Effectiveness and Safety of Everolimus Eluting Stent System(XIENCE V)in Patients with Atrial Fibrillation.Am J Cardiol.2014;113(7,Supplement):S3.
[20]Aoki J,Kozuma K,Awata M,et al.Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES(XIENCE V/PROMUS)in Japan.Cardiovasc Interv Ther.2018.doi:10.1007/s12928-018-0515-z
[21]Konishi A,Iwasaki M,Shinke T,et al.Favorable early vessel healing after everolimus-eluting stent implantation:3-,6-,and12-month follow-up of optical coherence tomography.J Cardiol.2018;72(3):193-199.
[22]Naito R,Miyauchi K,Konishi H,et al.Early definite stent thrombosis with everolimus-eluting stents.Clin Case Rep.2015;3(10):854-857.
[23]Nakajima Y,Itoh T,Morino Y.Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis.Catheter Cardiovasc Interv.2016;87(4):E137-142.
[24]Giudice P,Attisano T,Di Maio M,et al.Coronary vasomotion dysfunction after everolimus-eluting stent implantation.Interv Med Appl Sci.2014;6(4):178-182.
[25]Yano H,Horinaka S,Ishikawa M,et al.Early vascular responses after everolimus-eluting stent implantation assessed by serial observations of intracoronary optical coherence tomography.Heart Vessels.2017;32(7):804-812.
[26]Sabate M,Cequier A,I?iguez A,et al.Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction(EXAMINATION):1 year results of a randomised controlled trial.Lancet.2012;380(9852):1482-1490.
[27]Otsuka F,Vorpahl M,Nakano M,et al.Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus-and paclitaxel-eluting stents in humans.Circulation.2014;129(2):211-223.
[28]Chin-Quee SL,Hsu SH,Nguyen-Ehrenreich KL,et al.Endothelial cell recovery,acute thrombogenicity,and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings.Biomaterials.2010;31(4):648-657.
[29]Hiromasa T,Kuramitsu S,Shinozaki T,et al.Impact of total stent length after cobalt chromium everolimus-eluting stent implantation on 3-year clinical outcomes.Catheter Cardiovasc Interv.2017;89(2):207-216.
[30]Byrne RA,Joner M,Kastrati A.Stent thrombosis and restenosis:what have we learned and where are we going?The Andreas Grüntzig Lecture ESC 2014.Eur Heart J.2015;36(47):3320-3331.
[31]Hoppmann P,Kufner S,Cassese S,et al.Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice:Results of the ISAR-ABSORB registry.Catheter Cardiovasc Interv.2016;87(5):822-829.
[32]Basavarajaiah S,Naganuma T,Latib A,et al.Extended follow-up following"full-metal jacket"percutaneous coronary interventions with drug-eluting stents.Catheter Cardiovasc Interv.2014;84(7):1042-1050.
[33]Honari G,Ellis SG,Wilkoff BL,et al.Hypersensitivity reactions associated with endovascular devices.Contact Dermatitis.2008;59(1):7-22.
[34]Hermiller JB,Krucoff MW,Kereiakes DJ,et al.Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.JACC Cardiovasc Interv.2016;9(2):138-147.
[35]Zamiri P,Kuang Y,Sharma U,et al.The biocompatibility of rapidly degrading polymeric stents in porcine carotid arteries.Biomaterials.2010;31(31):7847-7855.
[36]Bae IH,Jeong MH,Lim KS,et al.Novel Polymer-Free Everolimus-Eluting Stent Fabricated using Femtosecond Laser Improves Re-endothelialization and Anti-inflammation.Sci Rep.2018;8(1):7383.
[37]Jeon H,Koo S,Reese WM,et al.Directing cell migration and organization via nanocrater-patterned cell-repellent interfaces.Nat Mater.2015;14(9):918-923.
[38]Sprimont P,Pierard S,Vanoverschelde JL,et al.Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients:a prospective non-randomized single-centre long-term comparison.Acta Cardiol.2014;69(5):523-531.
[39]Arroyo DA,Schukraft S,Kallinikou Z,et al.Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds:the MOVES trial.Open Heart.2018;5(1):e000624.
[40]Serruys PW,Ormiston JA,Onuma Y,et al.A bioabsorbable everolimus-eluting coronary stent system(ABSORB):2-year outcomes and results from multiple imaging methods.Lancet.2009;373(9667):897-910.
[41]Ota H,Mahmoudi M,Torguson R,et al.Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.Cardiovasc Revasc Med.2015;16(3):151-155.
[42]Vogt F,Blindt R,Hoffmann R,et al.TCT-824 Improved Safety And Efficacy Of A Novel Dual cRGD-And Everolimus-coated Coronary Stent Compared To Everolimus-eluting Stents In The Porcine Model.J Am Coll Cardiol 2013;62(18,Supplement 1):B249.
[43]Stone GW,Teirstein PS,Meredith IT,et al.A prospective,randomized evaluation of a novel everolimus-eluting coronary stent:the PLATINUM(a Prospective,Randomized,Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System[PROMUS Element]for the Treatment of Up to Two de Novo Coronary Artery Lesions)trial.J Am Coll Cardiol.2011;57(16):1700-1708.
[44]Ormiston JA,Webster MW,Armstrong G.First-in-human implantation of a fully bioabsorbable drug-eluting stent:the BVSpoly-L-lactic acid everolimus-eluting coronary stent.Catheter Cardiovasc Interv.2007;69(1):128-131.
[45]SabatéM,Windecker S,I?iguez A,et al.Everolimus-eluting bioresorbable stent vs.durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction:results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.Eur Heart J.2016;37(3):229-240.
[46]Choi HH,Kim JS,Yoon DH,et al.Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation:comparison with sirolimus-eluting stent using optical coherence tomography.Int J Cardiovasc Imaging.2012;28(3):491-497.
[47]张娜娜,魏广和,张韶辉,等.西罗莫司与依维莫司药物洗脱支架治疗非ST段抬高型急性冠状动脉综合征的疗效比较[J].中国循环杂志,2016,31(5):437-441.
[48]Onuma Y,Miquel-Hebert K,Serruys PW,et al.Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease:the SPIRIT II trial.EuroIntervention.2013;8(9):1047-1051.
[49]Claessen BE,Smits PC,Kereiakes DJ,et al.Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus-versus paclitaxel-eluting stents pooled analysis from the SPIRIT(Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)and COMPARE(Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice)Randomized Trials.JACC Cardiovasc Interv.2011;4(11):1209-1215.
[50]阮洁,蒋萍,苏晞.佐他莫司洗脱支架与依维莫司洗脱支架5年临床疗效比较[J].中国介入心脏病学杂志,2018,26(6):341-344.
[51]Gu H,Hua K,Li W,et al.Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent:A meta-analysis of randomized controlled clinical trials and observational studies.Int J Cardiol.2015;201:552-560.
[52]Sprimont P,Pierard S,Vanoverschelde JL,et al.Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients:a prospective non-randomized single-centre long-term comparison.Acta Cardiol.2014;69(5):523-531.
[53]Smits PC,Hofma S,Togni M,et al.Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent(COMPARE II):a randomised,controlled,non-inferiority trial.Lancet.2013;381(9867):651-660.
[54]Connelly M.Cognitive behavioral therapy for treatment of pediatric chronic migraine.JAMA.2013;310(24):2617-2618.
[55]Stone GW,Sabik JF,Serruys PW,et al.Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.N Engl J Med.2016;375(23):2223-2235.
[56]Miura K,Tada T,Kuwayama A,et al.Stent Fracture and Peri-Stent Contrast Staining After Everolimus-Eluting Stent Implantation-5-Year Outcomes.Circ J.2017;81(10):1514-1521.
[57]Kuramitsu S,Iwabuchi M,Domei T,et al.Response to letter regarding article,"incidence and clinical impact of stent fracture after everolimus-eluting stent implantation".Circ Cardiovasc Interv.2013;6(1):e10.
[58]Ji EY,Park GM,Kim DW,et al.Multiple Stent Fractures After Everolimus-Eluting Stent Implantation Causing Acute Myocardial Infarction:A Case Report.Medicine(Baltimore).2016;95(6):e2704.
[59]Park SJ,Ahn JM,Kim YH,et al.Trial of everolimus-eluting stents or bypass surgery for coronary disease.N Engl J Med.2015;372(13):1204-1212.
[60]Nomura T,Suzuki N,Takamura S,et al.Three-Year Clinical and Angiographic Outcomes After Everolimus-Eluting Stent Implantation in Patients With a History of Coronary Artery Bypass Grafting.Int Heart J.2016;57(2):158-166.
[61]Kadakia MB,Epps KC,Julien ME,et al.Early aneurysm formation after everolimus-eluting stent implantation.Circ Cardiovasc Interv.2014;7(2):266-267.
[2]Yang JH,Choi SH,Song YB,et al.Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction.Am J Cardiol.2013;112(5):623-629.
[3]Kong KL,Fong AYY,Mejin M,et al.PM222 Early Clinical Outcomes In Patients Electively Implanted With Everolimus And Non-Everolimus Drug Eluting Stents:Impact Of Platelet Function Testing Following Pretreatment With Aspirin And Clopidogrel.Global Heart.2014;9(1,Supplement):e108.
[4]Hayashi T,Kotani J,Ishibashi-Ueda H,et al.Thrombus-related focal in-stent restenosis after everolimus-eluting stent implantation.Heart Vessels.2014;29(2):273-277.
[5]Stone GW,Midei M,Newman W,et al.Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease:a randomized trial.JAMA.2008;299(16):1903-1913.
[6]Palmerini T,Kirtane AJ,Serruys PW,et al.Stent thrombosis with everolimus-eluting stents:meta-analysis of comparative randomized controlled trials.Circ Cardiovasc Interv.2012;5(3):357-364.
[7]Hasskarl J.Everolimus.Recent Results Cancer Res.2014;201:373-392.
[8]Martinet W,Verheye S,De Meyer GR.Everolimus-induced mTORinhibition selectively depletes macrophages in atherosclerotic plaques by autophagy.Autophagy.2007;3(3):241-244.
[9]Lebwohl D,Anak O,Sahmoud T,et al.Development of everolimus,a novel oral mTOR inhibitor,across a spectrum of diseases.Ann N Y Acad Sci.2013;1291:14-32.
[10]von Birgelen C,van der Heijden LC,Basalus MW,et al.Five-Year Outcome After Implantation of Zotarolimus-and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients:A Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiol.2017;2(3):268-276.
[11]Sotomi Y,Suwannasom P,Tenekecioglu E,et al.Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold:from bench to clinical use.Expert Rev Cardiovasc Ther.2015;13(10):1127-1145.
[12]Gatto P,Dumonteil N,Boudou N,et al.Incomplete stent apposition and very late stent thrombosis after everolimus eluting stent implantation and dual antiplatelet therapy interruption.Acase of OCT guided therapy.Int J Cardiol.2015;180:52-54.
[13]Ahn JM,Park GM,Cho YR,et al.Comparison of Platinum Chromium Versus Cobalt Chromium Everolimus-eluting Stent in Real World Practice:Outcomes from the Multicenter Prospective IRIS-DES Registry.Am J Cardiol 2013;111(7,Supplement):2B.
[14]Barbash IM,Minha S,Torguson R,et al.Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.J Invasive Cardiol.2014;26(4):154-160.
[15]Morino Y,Terashita D,Otake H,et al.Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction:results from a multicenter prospective optical coherence tomography study(MECHANISM-AMI 2-week follow-up study).Cardiovasc Interv Ther.2018.doi:10.1007/s12928-017-0507-4.
[16]Buszman PP,Michalak MJ,Pruski M,et al.Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.Cardiol J.2016;23(6):657-666.
[17]Calfon Press MA,Mallas G,Rosenthal A,et al.Everolimus-eluting stents stabilize plaque inflammation in vivo:assessment by intravascular fluorescence molecular imaging.Eur Heart JCardiovasc Imaging.2017;18(5):510-518.
[18]Shibata Y,Yano H,Horinaka S,et al.Everolimus-eluting stent suppresses chronic inflammatory reaction compared with bare metal stent in off-label patients.Eur Heart J.2013;34(Suppl 1):4807-4817.
[19]Karakulak UN,Yorgun H,?ahiner L,et al.OP-008 Evaluation of Effectiveness and Safety of Everolimus Eluting Stent System(XIENCE V)in Patients with Atrial Fibrillation.Am J Cardiol.2014;113(7,Supplement):S3.
[20]Aoki J,Kozuma K,Awata M,et al.Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES(XIENCE V/PROMUS)in Japan.Cardiovasc Interv Ther.2018.doi:10.1007/s12928-018-0515-z
[21]Konishi A,Iwasaki M,Shinke T,et al.Favorable early vessel healing after everolimus-eluting stent implantation:3-,6-,and12-month follow-up of optical coherence tomography.J Cardiol.2018;72(3):193-199.
[22]Naito R,Miyauchi K,Konishi H,et al.Early definite stent thrombosis with everolimus-eluting stents.Clin Case Rep.2015;3(10):854-857.
[23]Nakajima Y,Itoh T,Morino Y.Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis.Catheter Cardiovasc Interv.2016;87(4):E137-142.
[24]Giudice P,Attisano T,Di Maio M,et al.Coronary vasomotion dysfunction after everolimus-eluting stent implantation.Interv Med Appl Sci.2014;6(4):178-182.
[25]Yano H,Horinaka S,Ishikawa M,et al.Early vascular responses after everolimus-eluting stent implantation assessed by serial observations of intracoronary optical coherence tomography.Heart Vessels.2017;32(7):804-812.
[26]Sabate M,Cequier A,I?iguez A,et al.Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction(EXAMINATION):1 year results of a randomised controlled trial.Lancet.2012;380(9852):1482-1490.
[27]Otsuka F,Vorpahl M,Nakano M,et al.Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus-and paclitaxel-eluting stents in humans.Circulation.2014;129(2):211-223.
[28]Chin-Quee SL,Hsu SH,Nguyen-Ehrenreich KL,et al.Endothelial cell recovery,acute thrombogenicity,and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings.Biomaterials.2010;31(4):648-657.
[29]Hiromasa T,Kuramitsu S,Shinozaki T,et al.Impact of total stent length after cobalt chromium everolimus-eluting stent implantation on 3-year clinical outcomes.Catheter Cardiovasc Interv.2017;89(2):207-216.
[30]Byrne RA,Joner M,Kastrati A.Stent thrombosis and restenosis:what have we learned and where are we going?The Andreas Grüntzig Lecture ESC 2014.Eur Heart J.2015;36(47):3320-3331.
[31]Hoppmann P,Kufner S,Cassese S,et al.Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice:Results of the ISAR-ABSORB registry.Catheter Cardiovasc Interv.2016;87(5):822-829.
[32]Basavarajaiah S,Naganuma T,Latib A,et al.Extended follow-up following"full-metal jacket"percutaneous coronary interventions with drug-eluting stents.Catheter Cardiovasc Interv.2014;84(7):1042-1050.
[33]Honari G,Ellis SG,Wilkoff BL,et al.Hypersensitivity reactions associated with endovascular devices.Contact Dermatitis.2008;59(1):7-22.
[34]Hermiller JB,Krucoff MW,Kereiakes DJ,et al.Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.JACC Cardiovasc Interv.2016;9(2):138-147.
[35]Zamiri P,Kuang Y,Sharma U,et al.The biocompatibility of rapidly degrading polymeric stents in porcine carotid arteries.Biomaterials.2010;31(31):7847-7855.
[36]Bae IH,Jeong MH,Lim KS,et al.Novel Polymer-Free Everolimus-Eluting Stent Fabricated using Femtosecond Laser Improves Re-endothelialization and Anti-inflammation.Sci Rep.2018;8(1):7383.
[37]Jeon H,Koo S,Reese WM,et al.Directing cell migration and organization via nanocrater-patterned cell-repellent interfaces.Nat Mater.2015;14(9):918-923.
[38]Sprimont P,Pierard S,Vanoverschelde JL,et al.Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients:a prospective non-randomized single-centre long-term comparison.Acta Cardiol.2014;69(5):523-531.
[39]Arroyo DA,Schukraft S,Kallinikou Z,et al.Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds:the MOVES trial.Open Heart.2018;5(1):e000624.
[40]Serruys PW,Ormiston JA,Onuma Y,et al.A bioabsorbable everolimus-eluting coronary stent system(ABSORB):2-year outcomes and results from multiple imaging methods.Lancet.2009;373(9667):897-910.
[41]Ota H,Mahmoudi M,Torguson R,et al.Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.Cardiovasc Revasc Med.2015;16(3):151-155.
[42]Vogt F,Blindt R,Hoffmann R,et al.TCT-824 Improved Safety And Efficacy Of A Novel Dual cRGD-And Everolimus-coated Coronary Stent Compared To Everolimus-eluting Stents In The Porcine Model.J Am Coll Cardiol 2013;62(18,Supplement 1):B249.
[43]Stone GW,Teirstein PS,Meredith IT,et al.A prospective,randomized evaluation of a novel everolimus-eluting coronary stent:the PLATINUM(a Prospective,Randomized,Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System[PROMUS Element]for the Treatment of Up to Two de Novo Coronary Artery Lesions)trial.J Am Coll Cardiol.2011;57(16):1700-1708.
[44]Ormiston JA,Webster MW,Armstrong G.First-in-human implantation of a fully bioabsorbable drug-eluting stent:the BVSpoly-L-lactic acid everolimus-eluting coronary stent.Catheter Cardiovasc Interv.2007;69(1):128-131.
[45]SabatéM,Windecker S,I?iguez A,et al.Everolimus-eluting bioresorbable stent vs.durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction:results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.Eur Heart J.2016;37(3):229-240.
[46]Choi HH,Kim JS,Yoon DH,et al.Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation:comparison with sirolimus-eluting stent using optical coherence tomography.Int J Cardiovasc Imaging.2012;28(3):491-497.
[47]张娜娜,魏广和,张韶辉,等.西罗莫司与依维莫司药物洗脱支架治疗非ST段抬高型急性冠状动脉综合征的疗效比较[J].中国循环杂志,2016,31(5):437-441.
[48]Onuma Y,Miquel-Hebert K,Serruys PW,et al.Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease:the SPIRIT II trial.EuroIntervention.2013;8(9):1047-1051.
[49]Claessen BE,Smits PC,Kereiakes DJ,et al.Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus-versus paclitaxel-eluting stents pooled analysis from the SPIRIT(Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)and COMPARE(Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice)Randomized Trials.JACC Cardiovasc Interv.2011;4(11):1209-1215.
[50]阮洁,蒋萍,苏晞.佐他莫司洗脱支架与依维莫司洗脱支架5年临床疗效比较[J].中国介入心脏病学杂志,2018,26(6):341-344.
[51]Gu H,Hua K,Li W,et al.Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent:A meta-analysis of randomized controlled clinical trials and observational studies.Int J Cardiol.2015;201:552-560.
[52]Sprimont P,Pierard S,Vanoverschelde JL,et al.Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients:a prospective non-randomized single-centre long-term comparison.Acta Cardiol.2014;69(5):523-531.
[53]Smits PC,Hofma S,Togni M,et al.Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent(COMPARE II):a randomised,controlled,non-inferiority trial.Lancet.2013;381(9867):651-660.
[54]Connelly M.Cognitive behavioral therapy for treatment of pediatric chronic migraine.JAMA.2013;310(24):2617-2618.
[55]Stone GW,Sabik JF,Serruys PW,et al.Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.N Engl J Med.2016;375(23):2223-2235.
[56]Miura K,Tada T,Kuwayama A,et al.Stent Fracture and Peri-Stent Contrast Staining After Everolimus-Eluting Stent Implantation-5-Year Outcomes.Circ J.2017;81(10):1514-1521.
[57]Kuramitsu S,Iwabuchi M,Domei T,et al.Response to letter regarding article,"incidence and clinical impact of stent fracture after everolimus-eluting stent implantation".Circ Cardiovasc Interv.2013;6(1):e10.
[58]Ji EY,Park GM,Kim DW,et al.Multiple Stent Fractures After Everolimus-Eluting Stent Implantation Causing Acute Myocardial Infarction:A Case Report.Medicine(Baltimore).2016;95(6):e2704.
[59]Park SJ,Ahn JM,Kim YH,et al.Trial of everolimus-eluting stents or bypass surgery for coronary disease.N Engl J Med.2015;372(13):1204-1212.
[60]Nomura T,Suzuki N,Takamura S,et al.Three-Year Clinical and Angiographic Outcomes After Everolimus-Eluting Stent Implantation in Patients With a History of Coronary Artery Bypass Grafting.Int Heart J.2016;57(2):158-166.
[61]Kadakia MB,Epps KC,Julien ME,et al.Early aneurysm formation after everolimus-eluting stent implantation.Circ Cardiovasc Interv.2014;7(2):266-267.